Validation
Gene Symbol |
Curated Descriptions | Cell Lines | Isolations | Validations | Control-case | Tumor Stage & Subtype | Clinical Use | PMID |
|---|---|---|---|---|---|---|---|---|
| hsa-miR-155 | Our study showed that serum-circulating miR-145, miR-155, and miR-382 are present in exosomes. These miRNAs were previously proposed as noninvasive biomarkers to distinguish between BC patients and healthy individuals | ExoQuick exosome precipitation solution | scanning electron Microscopy,atomic force microscopy, anoparticle tracking analysis | 20 diagnosis of ductal carcinoma (case) 5 healthy donors (control) | stages I, III, and IV breast cancer | 30891102 | ||
| hsa-miR-145 | Our study showed that serum-circulating miR-145, miR-155, and miR-382 are present in exosomes. These miRNAs were previously proposed as noninvasive biomarkers to distinguish between BC patients and healthy individuals | ExoQuick exosome precipitation solution | scanning electron Microscopy,atomic force microscopy, anoparticle tracking analysis | 20 diagnosis of ductal carcinoma (case) 5 healthy donors (control) | stages I, III, and IV breast cancer | 30891102 | ||
| hsa-miR-130a-3p | Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence | ExoQuick | nanosight LM10 instrumen western blottingt | 16 breast cancer patients with recurrence (case) 16 breast cancer patients without recurrence (control) | Luminal (ER and/or PR + and HER2 -),HER2 (ER and/or PR +/- and HER2 +),TN (ER and PR and HER2 -) | recurrence | 29050253 | |
| hsa-miR-130a-3p | Hsa-miR-130a-3p inhibits migration and invasion by regulating RAB5B in human breast cancer stem cell-like cells | MCF7,MDA-MB-231 | ExoQuick Exosomal Extraction Kit | contrast microscope | 29746865 | |||
| hsa-miR-130a | Comparing the miRNAs in MDA-Exo to MCF-Exo showed a higher expression of tumorigenic mir-130a in MDA-Exo. it has been shown that mir-130a contribute to tumorigenesis of colon cancer by regulating TGB-β/Smad signaling | MCF7,MDA-MB231 | ultracentrifugation | electron microscopy | 24468161 | |||
| hsa-miR-128 | Hsa-miR-128 negatively regulates the level of Bax in MCF7recipient cells and inhibits cell proliferation | MCF7 | centrifugation | transmission electron microscopy,Nanoparticle Tracking Analysis | 27322220 | |||
| hsa-miR-1246 | Based on the selective enrichment and absolute abundance, we identified miR-1246, miR-122, miR-21, and let-7a as candidate exosome microRNAs that may serve as biomarkers indicative of breast cancer | ultracentrifugation, Exoquick-TC reagent (System Biosciences,Mountain View,CA,USA) | electron microscopy,nanoparticle tracking analysis,and western blot | 16 breast cancer plasma samples (case) 16 healthy plasma samples (control) | ER+/-,PR+/-,HER2+/- stages II, III breast cancer | 27608715 | ||
| hsa-miR-1246 | Hsa-miR-1246 promotes cell proliferation,invasion and drug resistance by targeting CCNG2 in breast cancer | MDA-MB-231 | ultracentrifugation | scanning electron and confocal microscopy | metastasis | 29216623 | ||
| hsa-miR-124-3p | Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence | ExoQuick | nanosight LM10 instrumen western blottingt | 16 breast cancer patients with recurrence (case) 16 breast cancer patients without recurrence (control) | Luminal (ER and/or PR + and HER2 -),HER2 (ER and/or PR +/- and HER2 +),TN (ER and PR and HER2 -) | recurrence | 29050253 | |
| hsa-miR-122 | Based on the selective enrichment and absolute abundance, we identified miR-1246, miR-122, miR-21, and let-7a as candidate exosome microRNAs that may serve as biomarkers indicative of breast cancer | ultracentrifugation, Exoquick-TC reagent (System Biosciences,Mountain View,CA,USA) | electron microscopy,nanoparticle tracking analysis,and western blot | 16 breast cancer plasma samples (case) 16 healthy plasma samples (control) | ER+/-,PR+/-,HER2+/- stages II, III breast cancer | 27608715 |